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Due to the limits of feed volume addition and the problem of amino acid counter ion, miscellaneous osmolyte, 
and cell growth inhibitor accumulation, the fed-batch mode of bioreactor operation for CHO cell production of 
protein therapeutics is inherently limited with respect to the cell densities and productivities that are achievable.  
Continuous or perfusion culture with cell retention can overcome some of these limitations, but suffers from the 
disadvantages of large volume media consumption, long times to reach peak cell densities, and complications 
with cell retention devices.  We will describe hybrid versions of continuous culture that overcome many of these 
limitations and utilize a unique and simple technology which allows cells to control their own rate of perfusion 
with continuous feedback.  Volumetric productivities of greater than 1 gram/L/day (more than double the 
optimized fed-batch culture) for several moderate specific productivity cell lines have been achieved with very 
modest medium volumes, comparatively simple bioreactor operations, and a batch length that fits in a standard 
fed-batch window.  Methods of operation and experimental results obtained at the pilot scale when coordinating 
these hybrid continuous cultures with a continuous downstream process will also be discussed.   
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